Pharma enters ‘age of uncertainty’ amid challenges from IRA, FTC and patent cliffs

It’s been a de­mand­ing year for the phar­ma in­dus­try. There’s a more ag­gres­sive FTC, a chang­ing FDA, tough mar­ket con­di­tions, and a le­gal fight over the drug pric­ing pro­vi­sions in the In­fla­tion Re­duc­tion Act.

Wel­come to phar­ma’s “age of un­cer­tain­ty,” ac­cord­ing to Eval­u­ate’s lat­est re­port, which de­scribes a world in which “work­ing out what kind of as­sets to de­vel­op or buy has be­come much more com­pli­cat­ed.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.